share_log

BioLife Solutions Announces the Divestiture of Its Stirling Freezer Business

BioLife Solutions Announces the Divestiture of Its Stirling Freezer Business

BioLife Solutions宣佈剝離其斯特靈冷凍機業務
PR Newswire ·  04/18 20:05

BOTHELL, Wash., April 18, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader biopharma markets, today announced that it has completed the divestiture of its wholly owned subsidiary Global Cooling, Inc. ("GCI" or "Stirling").

華盛頓州博塞爾,2024 年 4 月 18 日 /PRNewswire/ — 生物生命解決方案有限公司(納斯達克股票代碼:BLFS) (“BioLife” 或 “公司”)是爲細胞和基因療法(“CGT”)及更廣泛的生物製藥市場提供生物生產產品和服務的領先開發商和供應商,今天宣佈,它已完成對其全資子公司環球製冷公司(“GCI” 或 “斯特林”)的剝離。

Roderick de Greef, Chairman and CEO, commented, "After a thorough and extensive process, we're pleased to have completed the divestiture of the Stirling freezer business. The sale is expected to immediately eliminate several million dollars of quarterly cash burn and removes product warranty liabilities, which totaled $7.5 million as of December 31, 2023. Most importantly, we anticipate that this transaction will result in higher growth rates in total revenue and adjusted EBITDA, as well as gross margin expansion."

董事長兼首席執行官羅德里克·德格里夫評論說:“經過徹底而廣泛的過程,我們很高興完成了斯特靈冷凍機業務的剝離。此次出售預計將立即消除季度數百萬美元的現金消耗,並取消截至2023年12月31日總額爲750萬美元的產品保修負債。最重要的是,我們預計這筆交易將提高總收入和調整後的息稅折舊攤銷前利潤的增長率,以及毛利率的擴大。”

The transaction, which is structured as a stock sale, required $7 million in cash to remain on the balance sheet of GCI and the repayment of $2.6 million in GCI long-term debt. BioLife Solutions intends to file a Current Report on Form 8-K with the U.S. Securities and Exchange Commission containing the definitive agreement along with certain pro forma financial information.

該交易以股票出售的形式進行,需要700萬美元的現金才能保留在GCI的資產負債表上,並償還260萬美元的GCI長期債務。BioLife Solutions打算向美國證券交易委員會提交一份表格8-K的最新報告,其中包含最終協議以及某些預計財務信息。

About BioLife Solutions

關於 BioLife 解決方案

BioLife Solutions is a leading supplier of cell processing tools and services for the CGT and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage and distribution. For more information, please visit , and follow BioLife on LinkedIn and X.

BioLife Solutions是爲CGT和更廣泛的生物製藥市場提供細胞處理工具和服務的領先供應商。我們的專業知識通過提供在收集、開發、儲存和分發過程中保持生物材料健康和功能的解決方案,促進新療法的商業化。欲了解更多信息,請訪問並在 LinkedIn 和 X 上關注 BioLife。

Cautions Regarding Forward-Looking Statements

關於前瞻性陳述的注意事項

Certain statements contained in this press release are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "plans," "expects," "believes," "anticipates," "designed" and similar words are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings we make with the U.S. Securities and Exchange Commission, all of which are available at www.sec.gov. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by us. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in its expectations with regard to these forward-looking statements or the occurrence of unanticipated events.

本新聞稿中包含的某些陳述不是歷史事實,可能是1995年《私人證券訴訟改革法》所指的前瞻性陳述。諸如 “計劃”、“期望”、“相信”、“預期”、“設計” 等詞語和類似詞語旨在識別前瞻性陳述。前瞻性陳述基於我們當前的預期和信念,涉及許多難以預測的風險和不確定性,可能導致實際結果與前瞻性陳述所陳述或暗示的結果存在重大差異。對其中某些風險、不確定性和其他事項的描述可以在我們向美國證券交易委員會提交的文件中找到,所有這些文件均可在www.sec.gov上查閱。由於前瞻性陳述涉及風險和不確定性,因此實際結果和事件可能與我們目前預期的結果和事件存在重大差異。提醒讀者不要過分依賴這些前瞻性陳述,這些陳述僅代表截至本文發佈之日。我們沒有義務公開更新這些前瞻性陳述以反映在此之後發生的事件或情況,也沒有義務反映其對這些前瞻性陳述的預期的任何變化或意外事件的發生。

Contact:

聯繫人:

Troy Wichterman
Chief Financial Officer
(425) 402-1400
[email protected]

特洛伊·威奇特曼
首席財務官
(425) 402-1400
[電子郵件保護]

SOURCE BioLife Solutions, Inc.

來源 Biolife Solutions, Inc.

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論